San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s ...
DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
DexCom, Inc. ( NASDAQ:DXCM ) shareholders should be happy to see the share price up 12% in the last month. But ...
Insulet Corp. reported much better than expected fourth quarter results, following on Dexcom Inc.’s report of earlier than expected coverage decision from CMS for its just-approved G7 continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback